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INTRODUCTION 
IBK (Infectious Bovine Keratoconjunctivitis) is a bovine eye disease 
which is rarely fatal, but it may result in a major economic loss. The 
principal treatment method consists of topical applications of 
antibiotics and sulfonamide eye drops, powders, or ointments for a period 
of five to seven days. Because lacrimal fluid rapidly washes the drug 
from the eye, it is desirable to develop a more efficient method for the 
administration of the drug. 
To address this problem, a controlled drug release system has been 
developed and characterized for its suitability for this application. 
Hydrogels have been selected as the polymer for the ocular controlled 
release system, and tylosin tartrate, an agricultural antibiotic, has 
been chosen as the release system drug which is capable of treating IBK. 
The drug release rates for ring devices have been evaluated in a 
continuous flow apparatus. Also, batch-to-batch reproducibility of 
release characteristics for the copolymer formulations chosen has been 
checked. Two different hydrogel copolymer formulations have been 
studied: 90:10 mole percent and 25:75 mole percent of methyl 
methacrylate (MMA) and hydroxyethyl methacrylate (HEMA). 
2 
LITERATURE REVIEW 
Nature of Problem 
Infectious Bovine Keratoconjunctivitis (!BK) is a disease occurring 
perennially in all areas where cattle are raised. This disease is 
commonly called "pinkeye". It is caused by a bacteria, Moraxella bovis, 
which is found in discharges from the eyes and noses of infected animals. 
Signs of the disease may be divided into four stages: the first 
stage is exemplified by moist eyes or slight tearing; the second stage is 
the ulcerative stage associated with drooping of the eyelids; the third 
stage (or the period of vascularization) occurs when the corneal repair 
process predominates; the fourth stage is the time when the scar tissue 
is resolved. Occasionally, weakening of the cornea leads to rupture and 
subsequent loss of the eye. The disease may occur any time during the 
year, but it usually manifests itself most often during summer when 
disease-enhancing factors such as ultraviolet radiation and fly 
population are increased (Hughes, 1981). 
The average outbreak lasts about three weeks, with the largest 
economic damage associated with weight loss in beef herds and with a 
reduction in milk production (may be cut in half for infected dairy 
herds). These economic losses result from various causes. For example, 
cattle with severely diseased eyes tend to stay away from other cattle in 
order to protect their infected eyes and to reduce the pain caused by 
direct sunlight. This inactivity can result in a reduction of feeding 
and a decrease of growth rate and milk production. 
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Present Treatment Methods 
IBK is a contagious disease, so management of diseased cattle is 
effective and practical. Affected animals are placed in dark quarters, 
to avoid fly irritation and direct sunlight, and are separated from the 
herd. It is recommended that cattle should be treated with antibiotics 
or other chemo-therapeutic agents before they are returned to a herd. 
Fly control measures, sanitation, sprays, dusts, and systemic 
insecticides are also recommended. 
Once an infected animal is found in a herd, all animals should be 
treated. Various kinds of eye medications may be useful in preventing 
the development of secondary infections. Suggested treatment for IBK 
ranges from topical application of eye drops, ointments, or s~rays to 
continuous injection of a variety of antibiotic solutions and compounds 
containing chloramphenicol, oxytetracycline, penicillin-streptomycin 
(Jensen and Mackey, 1979; Blood et al., 1979), or tylosin (Burger, 1970; 
Rossoff, 1974; Hughes, 1981). The use of eye drops and sprays represents 
direct treatment techniques for infected eyes, but it is difficult to 
maintain therapeutic levels of drug in the tears and in the conjuntival 
sacs, and therefore repeated applications are necessary. 
Antiseptic eye drops such as boric acid, mercurials, argyrol, 
silver nitrate, and copper sulfate were used during the first 
half of the century. 
Zinc sulfate in a .1 :40 solution and ethidium bromide were found useful 
(Hughes, 1981). The eye drop type dosage form is easy to use, but 
suffers from inherent drawbacks. A great part of the medication is 
immediately diluted in the tear film as soon as the eye drop solution is 
instilled into the cul-de-sac, and is rapidly drained away from the 
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ocular cavity by constant tear flow. In order to maintain a continuous, 
sustained level of drug medication, frequent instillation of eye drops or 
an application of higher concentration of drug is necessary, but the loss 
of drug through lacrimal-nasal drainage system may result in some 
considerable side effects (Chien, 1982a). Eighty percent of an eye drop 
is lost immediately after instillation (information for humans; Gelatt et 
al., 1979). When sprays with a drug such as tylosin tartrate were 
applied twice daily, the clinical signs of IBK were eliminated within 5 
days (Ellis and Barnes, 1961). Even though the sprays have similar 
retention times as seen for eye drops, a spray results in less irritation 
than an eye drop. A treatment must be applied in the beginning of 
infection to achieve best results., 
For achieving the therapeutic efficiency of an ophthalmic drug,, 
viscosity-enhancing agents such as methyl cellulose are added into the 
eye drop preparation, or the ophthalmic drug is provided as an ointment 
to sustain intimate drug/eye contact. Unfortunately, these methods also 
do not yield a constant drug bioavailability, and they give only 
marginally more sustained drug/eye contact than the eye drop solution. 
Repeated medications are still required through a period of a few days. 
Recently, delivery systems (for humans) have been developed to 
prolong the retention time of a drug in the eye through the use of soft 
contact lenses or ocular inserts. Soft contact lenses are presoaked in 
eyedrop solutions. The effects of drug last 24 hours after application, 
and the drug concentration declines rapidly after that (Gelatt et al., 
1979). Ocular inserts, which were fabricated from insoluble or soluble 
polymers, were placed in the upper or lower conjunctiva! sac. This 
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appeared to overcome the difficulty of maintaining therapeutic drug 
concentration at the site of the infection. A controlled release device 
must be able to be inserted easily in the eye, and must be able to remain 
there during the course of the therapy. Also, the device must not cause 
tissue reaction • 
. In cattle, several forms of prolonged release devices have been 
tested. Hawley (1954) reported that an eye pellet can provide 
therapeutic levels of drug, such as terramycin in tears for up to 31 
hours. Certain polymers and copolymers such as polylactic acid, 
ethylene/vinyl acetate, polyglycolic acid, polylactic/polyglycolic acid 
composite and others have been used as controlled drug delivery system. 
Theodorakis et al. (1983) prepared an ocular insert which was made of 
composite of chloramphenicol sodium succinate (CASS) with polylactic acid 
(PLA). This was attached onto the third eyelid of cattle and rabbits. 
The inserts were retained in the eye at least 4 days, and achieved a 
therapeutic level of drug in ocular fluids of healthy cattle. On this 
basis, these inserts may be useful in treating IBK. The ocular inserts 
released CASS at a rate that diminished with time. The release kinetics 
did not follow the square root of time law or a first-order equation. 
Graham and Hibbs (1981) have developed a composite material for the 
prophylactic treatment of pinkeye. They applied attenuated Moraxella 
bovis directly to the eyes of cattle to provide cellular immunity to 
prevent bacterial infection. Attenuation of Moraxella bovis was 
accomplished by a heat treatment of pure cultures of Moraxella bovis 
which were isolated from active cases of pinkeye. The attenuated 
cultures may be formulated as a time release medication in the form of an 
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ocular insert. The ocular insert contained attenuated Moraxella bovis 
and an antibiotic. 
Structure and Lacrimal System of a Bovine Eye 
Structure of bovine eye 
The eye is ~he sense organ for vision. Within its protective 
casing, each eye has a large number of receptors, a lens system for 
focusing light on these receptors, and a system of nerves for conducting 
impulses from the receptors to the brain. 
The ocular layer of each eye is tough, fibrous and (except at the 
front) opaque to light. This is the sclera, or "white" of eye. At the 
front, and bulging forward, the transparent cornea replaces the sclera, 
and outside the cornea is the thin protective membrane called the 
conjunctiva. The inner surface of the upper and lower eyelids, both 
sides of the 3rd eyelid, and the anterior surface of the eye itself are 
covered with this layer. The conjunctiva is constantly cleaned and 
moistened by a salty, bactericidal fluid called tears. The tears are 
secreted by several lacrimal glands (Prince et al., 1960; Severin et al., 
1980). The lacrimal glands are located caudodorsally to the globe. 
Also, located in the medial canthus or corner of a bovine eye is a 
transverse sheet of thin translucent membrane, the "third eyelid" 
(nictitating membrane). The third eyelid of cow is leaf or shovel-shaped 
and thicker than in the horse. The schematic drawing of a bovine eye is 
shown in Figure 1. 
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A: Cornea 
B: Nie ti tating membrane 
--A 
C: Cartilage of nic ti ta ting 
membrane 
/B D: Lower eyelid 
FIGURE 1. Schematic drawing of a bovine eye (from Theodorakis et al., 
1983) 
Lacrimal apparatus 
The eye is protected by two mechanisms; blinking and the secretion 
of tears. Irritating partic.les and fumes are washed away from the 
sensitive cornea by the secretion of tears, and the surface of the globe 
is maintained in a normally moist cond-ition. Blinking, besides its 
protective function, prevents dazzle by a blinding light and keeps the 
exposed surface of the globe moist by spreading the lacrimal secretions 
and by preventing evaporation during sleep. Also, the act of blinking 
assists in the drainage of tears. 
The lacrimal apparatus consists of four structures (Figure 2); (1) 
lacrimal glands, (2) lacrimal canals, (3) lacrmal sac, and (4) 
nasolacrimal duct. Fluid secreted by the lacrimal glands washes over the 
eyeball and is swept up by the blinking. Tears drain through the 
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lacrimal canals from the punts to the lacrimal sac, which drains into the 
nasal cavity via the nasolacrimal duct (Pasquini, 1982; Severin et al,, 
1980). The eyeball is continuously irrigated by a gentle stream of fluid 
which prevents it from becoming dry and inflamed. Normally, the amount 
of lacrimal fluid renewed by frequent involuntary blinking movements is 
just sufficient to keep pace with its disappearance from the conjunctiva. 
However, an excessive formation and secretion of lacrimal fluid, or 
lacrimation, can occur when foreign bodies or other irritants get into 
the eye, when a bright light is shined into the eye, or when the cow is 
in emotional stress. 
~-,, 
- I ri' ----~ .. ,. ":~ ':~ 1toir~. \(, I~ -.\~'I'"". A. Position ol lac:rirnal ~ ··:~• .ipp.1ratus 
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. : 
' -~. ·. 
'1 
( ~-
'"':::::.~~·"·-,,·~'· , .......... -. .... 
1 ....... "' ...... """" •i..c·--.. , __ , ....  
·~-··''"'"''' _" __ , 
9. Lacrinul app;1ratus. 
_.,..... ·---·-· ·-~ ........ , .. _ .. , ... , ..... .. _.,.... 
='=-·--FIGURE 2. Lacrimal apparatus in relation to the bovine eye (from 
Pasquini, 1982) 
One of the most essential requirements for the anatomical and 
functional integrity of the cornea is a moist environment, The molsture 
within the conJunctival sac, the serous component of tear fluid, is 
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largely produced by the lacrimal gland, The nictitans glands also 
contribute a serous component of tear fluid. Through a number of ducts, 
tears reach the conjunctival sac at the upper fornix, mixed with the 
mucous products of the Harder's gland. The tear fluid maintains a well 
organized fluid film over the entire anterior surface of the eyeball. A 
good deal of this fluid is lost through evaporation while the eye is 
open. In the normal tear film, the evaporation rate is low because of 
the protective oily surface. No more than 20 to 25 percent of the total 
tears secreted (human) are lost by evaporation (Milder, 1970). 
Charac terisi tics of tear solution 
Tears form a clear, salty, slightly alkaline, watery fluid. The 
tear fluid contains lysozyme, whose bactericidal activity reduces the 
bacterial count in the conjunctival sac. Water constitutes 98-99% of the 
tear fluid, and thus the specific gravity is only slightly above unity. 
The viscosity is 1.053 to 1.405 centipoise, The osmolarity and the pH 
are of clinical interest in the preparation of drops for instillation 
into the conjunctival sac in order .to minimize discomfort and irritation. 
Modern studies have suggested that tear fluid is approximately isotonic 
with plasma. As discussed by Duke-Elder (1968), the osmotic pressure of 
human tears is equivalent to that of solutions of sodium chloride ranging 
in concentration from 0.903 to 1.014 gr NaCl/lOOg H
2
o; the range was 
considerable, but close to that of "physiological saline". The pH of 
tears is usually in the range of 7, 4 - 7, 5 (approximately as alkaline as 
plasma). 
Chemical constituents of tears can be divided into (1) 
nondiffusible substances of large molecular size and (2) 
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diffusible substances, which in turn are comprised of ionized 
and nonionized compounds, 
The chief nondiffusible constituent of tears is protein (concentration in 
the range from 0.2 to 0.6 wt. %). In electrophoretic studies, there are 
three main bands: serum albumin, serum globulin and lysozyme. Of these 
three, lysozyme has bactericidal properties. 
In general, its lytic properties depend on the reaction, the 
salt concentration and temperature. 
In some pathological conditions, such as conjunctiva! 
infections (kerato-conjunctivitis sicca and sustained 
epiphora), the lysozyme content of the tears falls. 
Other nondiffusible substances are mucopolysaccharides and lipids. The 
ionic component of tears includes cations such as Na+ and K+, and anions 
such as c1-, phosphate and thiocyanate. The concentration of Na+ is 
approximately equal to that of serum, or is above it. The concentrations 
of potasssium and chloride are greater in tears than in serum. 
Nonionized substances include glucose, urea, and amino acids. 
Measurement of tear flow .rate 
As discussed in Duke-Elder (1968), there is a constant output rate 
of tears which continues throughout all waking hours. There are various 
tests for measuring the flow rate of tears: for example, (a) Schirmer's 
test, (b) newer techniques based on introducing a dye and (c) photometry. 
Hoffmann and Spradbrow (1978) reported bovine tear flow rates 
obtained from two cattle using the catheterization method. Values 
between 0.18 to 1.86 ml/hr were measured. Another method is to cannulate 
the nasolachrymal duct and to use a suction pump. Slatter and Edwards 
(1982) repor.ted that the mean tear flow rate obtained from 327 collection 
/ 
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periods of 30 minutes for 11 cattle was l.96tl.84 ml/hr. They saw no 
evidence of a difference of tear flow rates between left and right eyes. 
Time of day of collection was not seen to have an effect on the tear flow 
rate. 
Controlled Release Systems 
The term controlled release (delivery) systems can ~e distinguished 
from sustained systems. The release mechanisms for sustained systems are 
sensitive to environmental conditions, while those of the controlled 
release systems are determined by the device (or system) characteristics. 
A controlled release system includes not only the notion of prolonged 
release characteristics, but more accurate, reproducible, and predictable 
release kinetics. 
Con trolled release systems may be classified according to physical 
mechanisms of release of the incorporated solute. Controlled release 
systems may be divided into porous and nonporous types according to the 
molecular structure of the polymer. Membrane-moderated controlled 
release systems can consist of a reservoir .(membrane) system and a matrix 
(monolithic) system. In reservoir systems, the bioactive agent is 
usually put into a device which is enclosed by a polymeric membrane, and 
the device is placed in contact with a dissolution medium (water or other 
biological fluid). The rate of drug release is controlled by its 
permeability between the membranes. Transport through these membranes 
may be described by Fick's first law of diffusion, 
dCm 
J = -D-dX (1) 
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where J is the flux, C is the membrane concentration of permeant, X is m 
the position of release concentration, and D is the permeant diffusion 
coefficient through the polymer. However, since solute concentrations in 
the membrane are difficult to measure experimentally, it is customary to 
determine solute concentration in the membrane by using the partition 
(distribution) coefficient, K, which is determined easily with a measure 
of solute solubility in the swollen polymer. The solute concentrations 
on either side of the membrane surface are in equilibrium with the solute 
concentration in the adjacent solution, C, as shown in Figure 3 (Baker 
and Lonsdale, 1974). 
Cm(O) = KC(O) at the upstream surface (X=O) ( 2) 
Cm(l) = KC(l) at the downstream surface (X=l) ( 3) 
Here, K is the distribution coefficient, which is the ratio of the 
solubility of the solute in the polymeric membrane to that in the liquid 
medium. 
In the steady state, equation (1) can be integrated to give 
(4) 
where 1 is the thickness of a slab membrane. From equations (2),(3), and 
( 4)' 
C(O)l 
CORC!RTRATION 
~NTIL\T!D 
SOLUTIOJll SlDB 
13 
C(l) 
0 ~-·----'l<EMBRANE""'"""~----!1· 1 DILUTE SOT.trrION THICKNESS SIDE 
FIGURE 3. Schematic representation of the concentration gradient across 
a membrane (from Baker and Lonsdale, 1974) 
J = DK AC 
1 (5) 
where ~c is the difference in concentrations on two sides of a membrane. 
If you have a constant activity sourse, the release rate of solute does 
not depend on time. This is commonly referred to in the literature as 
"zero order release". The release rate of this system will be constant, 
and for a slab, is represented using the equation (6). 
ADK AC 
where A is the surface area of the .slab. For a cylinder, the steady 
state re:).ease rate is given by 
2 hDK~C 
ln[ro) 
ri 
(6) 
(7) 
where r
0 
and ri are the outside and inside radius, respectively, of the 
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cylinder and h is the length of the cylinder. For the sphere, 
4ltDKAC (8) 
The above, for slabs and cylinders, assumes one-dimensional diffusion. 
This occurs under the assumptions of thin layer membranes for slabs and 
long cylinders for cylindrical systems. 
On the other hand, .for varying concentration experiments (Le, 
nonconstant sources), the release rate falls exponentially. This is. 
called "first order release". 
Although constant activity source reservoir systems give constant 
release behavior in the steady state, they will initially exhibit release 
rates higher or lower than the steady state value. This is due to the 
burst effect and the time lag. The burst effect may cause the device to 
release at an initially high rate depending on the history of the device. 
The time iag means that a device which is used immediately requires time 
to establish the concentration gradient within the membrane. 
Drug Release from a Matrix System 
In matrix (monolithic) systems, the bioactive agent (such as a drug) 
is mixed with the membrane (either as dissolved molecules or as dispersed 
solid drug particles). The solubility of the solute in the polymer 
matrix becomes a controlling factor in the mathematical modeling of these 
systems. 
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Matix systems can be classified four different types: 
i.. Dissolved systems in which the initial solute loading is below 
or at the solubility limit (saturated solubility) in the 
polymer. Then, release is achieved by simple molecular 
diffusion through the polymer. Thus, the rate of release is 
dependent upon the initial drug load. The diffusion coefficient 
is dependent upon the properties of the drug and the polymer 
matrix. 
2. Dispersed systems in which solute is dispersed as solid 
particles within polymer because the solute loading is above the 
solubility limit. In this case, dissolution of the solute in 
the polymer becomes the limiting factor in the releasing 
pattern. 
3.. Porous systems which are analogous to dispersed systems except 
that the initial drug loading is sufficient to produce 
continuous macroscopic pores of channels. The release rates are 
dependent upon transport within these solvent-filled pores or 
channels formed due to leaching of the solute. 
4. Reservoir-dispersed matrix systems (or porous reservoir systems) 
which are analogous to the dispersed system except that a 
barrier layer is present at the surface of the device which is 
of much lower permeability to the drug than is the bulk polymer 
matrix. 
Various derivatives of hydroxyalkyl methacrylates have been utflized 
for matrix devices because they have the following advantages: (1) 
nontoxicity, (2) high biocompatibility, (3) high permeability to both 
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hydrophobic and hydrophilic solutes, and (4) variable permeability, 
/ 
depending upon copolymer composition and crosslink density. 
The major advantages of a matrix system are that the system can be 
made easily and that a drug will not be released suddenly upon rupture. 
The maJor disadv·antage is that the solute release rate will decrease with 
time. The release kinetics from matrix systems are influenced by the 
initial drug loading and the geometry of devices. As the initial drug 
loading is increased, the matrix will become porous as drug is leached 
from the polymer. Thus, the free volume for diffusion increases as a 
result of the voids by the leached drug. This may bring changes in the 
effective diffusion coefficient of drug in the matrix phase. In addition 
to the initial drug loading effect, the geometry of these systems 
provides insight into the ·release characteristics of a polymer matrix. 
An example of a typical release profile is shown in Figure 4, where 
the release rate for progesterone from a silastic cylinder is plotted 
versus time (Cardinal, 1984a). 
The initial release rate in Figure 4 is very high relative to that 
seen at long times. In fact, this high release rate.may not only reach a 
toxic level for a drug with a narrow therapeutic index, but aiso may 
result in a short life for ·the device with a drug which has to be 
maintained at a therapeutic level for a long time. 
Next, the declining release rate has been explained by 
J. R. Cardinal ( 1984b). In a polymer containing a dispersed drug, a zone 
of depletion is formed as drug is released from the matrix system in 
Figure 5. A pictorial representation of the changes in this zone with 
time has been given by Roseman and Higuchi (1970). If the matrix is an 
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FIGURE 4. Typical profile for the variation in the release rate with 
time for a polymer matrix device in which the active agent is 
dispersed (from Cardinal, 1984a) 
infinite slab, the surface area at the receding drug boundary is 
constant. The flux of drug away from this surface will follow a path 
which is perpendicular to the surf ace. Therefore, by Fick' s first law, 
the concentration gradient in the zone of depletion will be linear. As 
the thickness of the zone increases, the diffusing distance will increase 
with time. Since flux is inversely proportional to the zone thickness, 
the release rate will decrease with time. 
For other devices (e.g., cylinders or spheres), the flux of the drug 
will also follow the same pattern as seen for slabs. However, the volume 
of the depletion zone will increase rapidly from the surface, and the 
concentration gradient is nonlinear within the zone of depletion. Thus, 
the release rate will decrease more rapidly with time. 
I= 11 
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I = I 2 
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Cylindrical Devices 
I= '2 
Dispersed 
Zone 
D Depleted 
Zone 
FIGURE 5. Schematic representation of the change in the dispersed and 
depleted zones of matrix devices with time ( t 2>t1) (from Cardinal, 1984b) 
In order to achieve a constant release rate, a number of methods 
have been developed. One approach is to design a device which has an 
increasing surface area of the zone of depletion with time. This method 
has been utilized by Brooke (1974), Lipper and Higuchi (1977), Hsieh et 
al. (1983) and Theeuwes (1980). A second approach is to incorporate a 
rate limiting barrier at the surface of the system, such as to include a 
crosslinked surface region, to alter the water content, or to dip coat 
and thus to establish a barrier layer. A ~hird approach is to have ·an 
aqueous boundary layer which can provide a significant resistance to drug 
release by using an inherent property of the matrix and the drug. A 
fourth approach is to control the rate of swelling of the matrix in the 
fluid medium. 
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Most of \:he mathematical models for controlled release kinetics 
presented in the literature have been derived with the assumption of a 
boundary condition of zero (and constant) solute concentration at the 
interface of the device. This condition requires the. complete 
elimination of boundary layer effect, such as by high agitation during 
the release experiment. Recent mathematical models and equations show 
the solution for certain boundary conditions. 
Baker and Lonsdale (1974) have developed approximations for release 
equations (refer to Table 1). These equations are in the form of 
infinite series (infinite slab or infinite cylinder), and include the 
data obtained from the short and long time approximations. In the case 
of the slab, the early time approximation provides an excellent fit in 
the range of Mt/M.,<0.6 where Mt is the mass of drug released by time and 
M.,is the total mass of drug. The late time approximation is valid in the 
range of 0.4 <Mt/M.,.<LO. For the cylinder, the early time approximation 
fits when Mt/M~<0.4, whereas the late one is valid in the range of Mt/M~ 
)0.6. In the case of the sphere, the early time approximation fits when 
Mt/M~<0.4, whereas the late time approximation is good in the range where 
It is clear that when slabs of monolithic devices are kept at a 
constant external solute concentration, the fractional release (M /M ) is 
t "' 
proportional to the square root of the release time over the first 60 % 
of release. After that, the fractional release decays in an exponential 
manner. However, in the dispersed drug system, the release rate falls 
according to the t~o. 5 law es sen ti ally throughout the life time. 
Solutions for other boundary conditions are available in the li.teratui:'e. 
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TABLE 1. Fractional release and release rate for a matrix device in 
which the active agent is dissolved 
Device 
geometry 
Slab 
Early time Late time 
Mt 8 - - 1 _ .. 
Moo - 1i1 
dMt 8DMoo -1l2Dt 
Cit = -2- exp( 2 ) 
1 1 
Mt Mt 2 
Cyli!lder 4 (Dt )0.5 _ Dt 4 [-{2.4052 Dt] M,. = M .. = 1 - exp itr2 r2 (2.405) 2 r2 
dMt/M 00 
2(_D_)0.5 _ 
D dMt/M00 _ 4D [-(2.405)
2Dt] 
dt = r2 dt 
- - exp 
1tr 2 t r2 r2 
Sphere 
Mt 
6<nt )o.5 _ 
3Dt Mt 6 -it2Dt 
M.., = -;z M., = 1 - j!Z exp( 2 ) itr2 r 
dMt/M.., 
3(_D_)0.5 _ 
3D. dMt/M .. 
2 
6Dt Cit Dt) 
dt = r2 dt = -- exp l[r2t r2 r2 
-------------------------------~-----------------------------------------
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Ocular Application of Controlled Release Systems 
When drug delivery to the eye is used, the duration of drug activity 
must be adequate, and the drug levels attained must be uniform so that 
the frequency of drug administration can be minimized. Thus, the 
invention of suitable ocular inserts will be more valuable than other 
methods of drug delivery as the invention would provide drug availability 
in the eye at a constant level for long periods of time. 
The eye has been considered to be a useful site for controlled 
release systems. Compared to other body sites, it is relatively easy for 
devices to be inserted into and to be removed from the eye. An insert is 
readily prepared by dissolving a drug and a polymer in a solven't. The 
solvent is then evaporated to form a thin film of the polymer which is 
made into the various shaped systems such as a square, rectangle, or 
doughnut, for example. Two ocular polymeric systems, Ocusert and 
Lacrisert, are already commercially available. 
The Ocusert is a membrane controlled reservoir system used in the 
treatment of glaucoma. The active agent of this insert is pilocarpine. 
The polymer used in the Ocusert is a ethylene-vinyl acetate copolymer. 
Pilocarpine is surrounded on both sides with two polymer membranes. 
There are two different systems of Ocusert. One releases pilocarpine at 
20 ug/hr (Pilo-20), and the other at 40 ug/hr (Pilo-40). Both systems 
display a "burst" effect. The major advantages of using Ocusert include: 
(1) longer duration of drug action (up to 7-8 days) (2) convenience of 
once a week application, and (3) better patient compliance, with the 
therapy. However, there are problems of insertion, retention, leakage, 
and discomfort. 
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Lacrisert is valuable for the treatment of a dry eye. This device 
is a rod-shaped preparation (1.27 mm diameter, 3.5 mm in length) composed 
of 5 mg of hydroxypropyl cellulose, a water soluble polymer. The 
Lacrisert is inserted into the eye with a special reusable applicator. 
The system is placed in the coi:ijunctival sac where it softens within 1 
hour, and comple.tely dissolves within 14 to 18 hours. This device acts 
to stabilize and thicken the precorneal tear film, and to prolong the 
tear film breakup time which is usually accelerated in patients with dry 
eye states. The difficulty of using Lacrisert is insertion (Conn and 
Langer, 1984). 
Ozawa et al. (1983) have prepared ocular inserts impregnated with 
antibiotics for trachoma therapy. In in vitro experiments, they found 
that the release rate of a drug with relatively high solubility was 
influenced by the solubility of drug in water. A drug with low 
solubility in water had a constant -release pattern when the water content 
of the hydrogel insert was more than 30%. In this case, the stirring of 
the solution increased the release rate. However, for a drug with high 
solubility, the rate determining step of the release was the diffusion of 
the drug within the gel. Consequently, a small change of water content 
of the hydrogel affected the release rate, al though the stirring of the 
solution had little effect. The drug release rate was a little higher in 
vivo than in vitro for the low solubility drug case. In addition, they 
suggested that ocular inserts should meet the following three criteria: 
1. Release kinetics of the effective drug from the insert should be 
zero or nearly zero order for a long time. 
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2. The insert should not be harmful when retained in the eye for a 
long time. 
3. The insert must be retained easily in the eye and must cause no 
patient discomfort. 
Several ocular inserts were suggested as the treatment system for 
providing pinkeye therapy for cattle. Hawley (1954) has used an eye 
pellet tJi.at provided therapeutic concentrations of terramycin in the eye 
for 31 hours. However, these eye tablets used tetracaine hydrochloride 
to reduce irritation from the tablet. Tetracaine has a severe inhibitory 
effect on the healing of injured cornea (Slatter et al., 1982). 
Theodorakis et al. (1983) have prepared an ocular insert which was made 
from a composite of CASS with PLA. The insert was retained in the eye at 
least 4 days and maintained therapeutic levels of drug in the eye of the 
rabbit in vivo. Hughes and Pugh (1975) tested the retention of plastic 
tubular rings. They did not report any drug incorporation or drug 
release experiments for bovine eyes. They emphasized that the retention 
of devices in the eye was dependent on the size (a range of 135 to 140 mm 
in circumference was satisfactory in their study) and the shape of 
device. They suggested that the use of the ring design and that a 
biodegradable matrix containing antibiotic could provide a good treatment 
method for the pinkeye of cattle. Punch et al. (1985) have used a 
soluble and an insoluble collagen film impregnated with gentamicin. For 
these collagen inserts, they found that soluble collagen films released 
significantly higher levels of antibiotic than the insoluble films, and 
that.soluble collagen films maintained the therapeutic levels necessary 
to treat Moraxella bovis for only 24 hours. The inserts showed no 
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irrftant properties when initially placed in the eye, and were well 
tolerated by the cow in contrast to their previous studies using 
hydrophilic contact lenses (Slatter et al., 1982) in which corneal edema 
was developed in some cattle right after insertion. 
Hydrogels for Controlled Drug Delivery 
Hydrogels may be prepared by different procedures of polymerization 
of hydrophilic monomers or of chemical modification of existing polymers. 
Hydrophilic polymers like HEMA are water-swollen gels with poor 
mechanical properties. Therefore, their application in a pure state is 
very limited. They must have an adequate number of hydrophilic groups to 
permit swelling (no dissolution) in water, but this decreases their 
mechanical stability. The hydrophilic monomers are usually copolymerized 
with hydrophobic monomers. Hence, the hydrophilicity of hydrogels can be 
modified by use of less water soluble monomers (e.g., MMA) for control of 
the mechanical strength and the degree of swelling. Hydrophilic monomers 
are mixed with hydrophobic ones in different ratios to yield hydrogels 
with a wide range of water con ten ts (Pis kin, 1984) • Copolymeriza ti on of 
HEMA with MMA leads to poorly swollen hydrogels which have been reported 
to give an almost zer.o-order release of low molecular weight solutes for 
long periods of time ( Cowsar et al., 1976). 
Hydrophobic polymers are provided to make uncrosslinked release 
devices by compression of powdered polymer or by dissolution of the 
polymer, followed by evaporation of the nontoxic solvent. Polydimethyl 
siloxanes (PDMS) and ethylene-vinyl acetate (EVA) copolymers are 
available. On the other hand, drug delivery systems based on synthetic 
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biodegradable polymers have used mainly polylactic acid, polyglycolic 
acid and their copolymers. 
Since hydrogels consist of hydrophilic macromolecules crosslinked· to 
form a three-dimensional network, their permeability for low molecular 
weight solutes has been exploited in designing sustained release devices 
(Schacht, 1984).· Also, this material is stable to varing pH, temperature 
and tonicity. Hydrogels in contact with aqueous solutions will swell to 
some equilibrium value. The equilibrium water content (EWC) is expressed 
by; 
EWC(%) = weight of swollen gel - weight dry gel xlOO weight of swollen gel 
This water content in a hydrogel influences the biocompatibility of 
polymer surfaces. The degree of hydration of hydrogels also affects the 
rate of release of drug. The equilibrium water content of a hydrogel is 
affected by the nature of the hydrophilic monomers used in preparing the 
polymer or copolymer, the nature and density of the crosslinks, and such 
factors as the temperature, tonicity and pH of the hydrating medium 
(Pedley et al., 1980), but poly(HEMA) is little affected by variations in 
these factors (equilibrium water content of 40 %) • A copolymer of HEMA 
with hydrophobic monomers, such as styrene or methyl methacrylate, will 
have less than 40 % water content. More hydrophilic monomer combinations 
can provide hydrogels with water contents in excess of 90 %. Collett et 
al. (1980) observed that the hydration of HEMA was influenced by the 
method of preparation and by the use of different solutes for hydrogel. 
They used HEMA as a monomer, 0.875 w/o of ethylene glycol dimethacrylate 
as the crosslinking agent, 40 w/o water, and 0.2 w/v of ammonium 
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persulfate as a chemical initiator. Other were prepared using a dose of 
300K rad of Y-radiation. Swelling properties and the degree of hydration 
of hydrogel were estimated from measurement of weight changes of gels 
immersed in water, and O.SM aqueous solution of some substances including 
NaCl, urea, and sucrose. The results showed that NaCl and sucrose caused 
dehydration of the gels probably due to an osmotic effect, whereas urea 
increased the hydration. 
The presence of the persulfate initiator increased the 
hydration rates and equilibrium water contents, compared with 
those seen in gels produced by irradiation. 
The magnitude of the permeability of a drug in a hydrogel matrix 
depends on the type of drug, the polymer composition, the water content 
in the hydrogel, and the amount and nature of the crosslinking agent 
(Schacht, 1984). The diffusion coefficient will decrease with increasing 
crosslinking density due to a reduced pore size and a decreased fraction 
of water. Therefore, the dissolution-diffusion process dominates the 
permeation mechanism. Schacht (1984) has obtained data for various 
crosslinker densities, and has indicated that the rate of release of 
procaineamide hydrochloride from hydrogels decreases as increasing 
amounts of crosslinking agents are added to the polymerization mixture. 
Water-swollen hydrogels with high degrees of swelling can provide 
rate-controlling barriers for diffusion of water-soluble drugs (Graham 
and McNeill, 1984). 
In addition, the drug release rate from a trilaminate delivery 
system by Olanoff et al. (1979) can be controlled by the device geometry, 
coating membrane thickness, disk surface area, drug loading and membrane 
coating copolymer composition. 
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Increasing disk surface area available for diffusion by 1.88 
times (0.709 - 1.33 cm2) produced a proportional increase in 
the release by 1.8 times (0.54 - 0.97 ug/day). 
Correspondingly, increasing the coating membrane thickness by 1.73 times 
(0.081 - 0.14 mm), holding surface area constant, decreased the release 
rate by 1.43 times, Increasing the drug loading in the core material by 
an order of magnitude from 0.02 to 0.2 milligrams of drug per milligram 
of total core weight increased the release rate by 16 times when 
corrected for a difference in membrane thickness. The higher increase 
than predicted in the release rate is probably due to the osmotic effects 
that become significant for core materials with higher drug loading, 
There were effects of varying the coating membrane composition; a 
hydrophilic coating copolymer (22:78 mole of ratio of HEMA:MMA) had a 
higher release rate than that of a relatively hydrophobic coating 
copolymer (2:98 HEMA:MMA). Rhine et al. (1980) also reported that 
fabrication parameters such as drug particle size,. drug loading and 
matrix coating significantly affected release kinetics in sustained 
macromolecule release. The release rate increases caused by increases in 
the particle size may result from the formation of larger channels or 
pores in the polymer matrix. Similarly, increased loading may provide 
simpler pathways and greater porosity for diffusion, both of which would 
facilitate the movement of water into the matrix and protein out of the 
matrix. Good and Mueller (1980) have shown the existence of a new 
diffusion mechanism which relies heavily on s true ture and thermodynamic 
interactions within a crosslinked polymer network, The networks 
described in their paper are composed of two component systems: the 
"macromer" component is a hydrophobic oligomer of butane oil while the 
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"main chain" is hydrophilic pHEMA (poly hydroxyethyl methacrylate). 
These networks were achieved by simultaneous copolymerization and 
crosslinking of pHEMA in the presence of the macromer, polytetramethylene 
oxide. The authors have shown that the usefulness of hydrogels can be 
expanded by using a structure based on 2-component systems in which the 
hydrophilic balance is adjusted to provide for the desired release rates 
for an enclosed solute. 
In Vitro Evaluation of Controlled Release of Drugs 
In order to develop a controlled release drug delivery system and to 
construct the controlled release rate profiles of drug from the device, 
the work requires the design of a proper in vitro drug elution system 
which will permit the accurate evaluation and analysis of the con trolled 
release profiles prior to the initiation of more costly animal testing. 
Analytical sensitivity of the drug assay technique, long-term maintenance 
of a sink condition, hydrodynamic characte.ristics of solution diffusion, 
reproducibility of sampling, and the volume and temperature of the system 
are important design parameters in choosing an elution system. 
Drug elution systems are divided into two types: a continuous flow 
apparatus or a constant rotation apparatus. Both of them are ideal for 
the measurement of in vitro drug release rate profiles. The continuous 
flow apparatus has been designed and used by Kalkwarf et al. (1972) and 
Roseman and Higuchi (1970). A typical setup is illustrated in Figure 6. 
This apparatus is composed of the reservoir for the elution 
solution, a peristaltic pump, a drug elution column and a thermostatic 
bath. A prototype of a drug delivery device is positioned in a drug 
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SALINE RESERVOIR PERISTALTIC PUMP THERMOSTATIC BATH. 37°c 
FIGURE 6. Schematic diagram of a continuous flow apparatus (from Chien, 
1982b) 
elution column which is thermostated at 37°c, and the device is exposed 
to a continuous flow of elution solution by using a peristaltic pump. 
Distilled water, isotonic saline and 3% isotonic solution of bovine serum 
albumin have been used as an elution ·solution. Samples from the effluent 
of the systems are then collected and assayed at various time intervals 
(Kalkwarf et al., 1972). As the flow rate of elution solution is 
increased, the rate of drug release also increases, and eventually 
reaches a plateau level. The in vitro release of progesterone from a 
matrix-type polyethylene drug delivery device using this apparatus was 
li~ear for a Q (rate of drug release) vs. t0.5 (time) plot (i.e., was 
found to follow a Q versus t0.5 relationship; Chien, 1982b). Kalkwarf 
and coworkers (1972) suggested that sink conditions were maintained 
during the test. Direct evaluation of drug concentration in the elution 
solution becomes extremely difficult and labor-intensive. 
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Another method for in vitro evaluation is the use of a constant 
rotation apparatus. Chien and his associates (1974) developed a constant 
rotation apparatus which was relatively simple in design and easy to 
build. The polymeric drug delivery device is mounted in a circular 
plexiglass holder (with a spin bar at the center of the holder), and then 
the spin bar is rotated in the elution solution at constant rotation rate 
to achieve the constant solution hydrodynamics required. The release 
rate has a similar pattern (linear Q vs. t0.5 relationship) to that of a 
constant flow appara'tus. In a drug elution system, the effect of 
temperature adjustment is one of the important factors in the 
thermodynamics of controlled release drug. The temperature is normally 
adjusted to 37°C to approximate body temperature. This temperature 
influences the in vivo evaluation. Y. W. Chien (1976) has reported that 
the Q vs. t0.5 drug release profile is observed to be 
temperature-dependent and is linked to three energy-activated steps: 
dissolution and diffusion of drug molecules in the polymer structure, and 
dissolution of drug molecules from a crystal lattice. 
Both drug elution systems are capable of maintaining a sink 
condition for better simulation of a biological in vitro/in vivo 
relationships. The in vitro/in vivo relationship established can then be 
applied to the design of a desirable drug release device. 
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PROPOSED TREATMENT METHOD 
Design Fae tors 
Selection of drug 
A wide range of astringents, antiseptics, and antimicrobial agents 
has been used for the treatment of IBK. Among these treatment drugs, 
penicillin and streptomycin have been used widely to treat IBK, but they 
are not as effective as certain other drugs. Tetracycline, erythromycin, 
and tylosin are effective drugs against Moraxella bovis infection. Of 
these three, tylosin has an inhibitory concentration as low as 0.63 ug/ml 
(as cited in Leytem (1984)). Tylosin (molecular weight 916.14) is a 
marcrolide type antibiotic isolated from a strain of Streptomyceles 
fradiae found in soil from Thailand (Hamill et al., 1961). The structure 
of tylosin is shown in Figure 7. 
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FIGURE 7• Molecular structure of tylosin (from Windholz et al., 1976) 
This antibiotic is essentially nontoxic, nonirritating to the eye 
and conjunctival sac, stable and readily soluble in water (Ellis and 
Barnes, 1961). Tylosin tartrate (mol. wt. 1066.2) is commercially 
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available as an agricultural antibiotic (Burger, 1970), is soluble in 
water at concentrations greater than 300mg/ml, and is stable at room 
temperature in aqueous solutions (pH 4-9) for at least one month (Ose and 
Barnes, 1960). 
Treatment device 
The treatment device must be designed for prolonged retention in the 
eyes of cattle. In addition, the device should be easy to insert and 
should not induce tissue reaction. Hughes and Pugh (1975) have examined 
these factors to design an ocular insert for cattle. They have evaluated 
ring devices fabricated from intrademic polyethylene, medical grade 
polyvinylchloride, and nylon surgical tubing. Insertion of ring devices 
was no problem except that the ring had to be the proper size to fit into 
the conjunctiva! sac. Local eye reaction to the ring devices was 
minimal, and ranged from an increased tear pooling initially, to an 
increased mucous secretion after prolonged retention. These ring type 
devices were retained in the cattle eyes up to 19 days. The authors have 
reported that the long term retention of a ring device was made possible 
with rings having a circumference smaller than that of the conjunctiva! 
sac, but larger than that of the globe of the eye. If the ring is too 
large or too small, the ring tends to be forced out and is easy to 
distort. If these criteria are met, the ring devices will be uniquely 
suited for use in the bovine eye (which is anatomically different from 
that of human). Therefore, this ring-shape was chosen as the 
configuration of the proposed treatment devices. 
• 
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Material for device 
The material used for construction of the ring devices must be rigid 
enough to retain its ring shape, but should be flexible enough to conform 
to the shape of the conjunctiva! sac. Also, the smooth surface of the 
ring device is necessary to prevent eye irritation. Tne membrane coating 
material of the ring device should be biocompatible, and be capable of 
sustaining the drug release for the required period. As mentioned above, 
hydrogel is one of the materials which can satisfy all the above 
conditions. A copolymer of HEMA and MMA will be used as the fabrication 
material. 
Design of the Apparatus for Release Experiments 
The development of an in vitro method that can determine the release 
machanism of a controlled released release device is a very important 
step in evaluating potential drug delivery systems prior to in vivo 
testing. A continuous flow apparatus can be applied to study the drug 
elution system of our matrix device. The design is similar to the actual 
eye in which the drug delivery system will be used. The block diagram 
for modeling the drug release appartus is shown in Figure s. 
This continuous flow apparatu.s is composed of the reservoir for the 
elution solution, a constant flow pump, drug elution system and 
thermostatic bath. The drug elution system is designed to be close in 
function to the lacrimal apparatus in the eye as shown in a schematic 
comparison in Figure 9. 
RESERVOIR FOR 
ELUTION SOLUTION 
t· 
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EL UT.ION 
SYSTEM 
SAMPLING 
AND 
ANALYSIS 
FIGURE s. The block diagram of ocular drug release apparatus 
EYE ROUGH MODEL ELUTION SYSTEM 
FIGURE 9. Drug elution system for ocular drug release device 
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Quantitative Design Parameters 
Required drug release rate 
In order to design an optimum release device for treating pinkeye, 
it is very important to determine the release characteristics of the 
device. The variables influencing release profile are the duration of 
the treatment of drug and mininmum and maximum concentrations required in 
treating the disease within a given period. Recovery times from pinkeye 
can not be clearly determined because of the difference in healing times 
depending on the severity of the disease (Blogg, 1980). To ensure a 
sufficient treatment duration, the prolonged device will be designed to 
release tylosin tartrate for at least 7 days. If a minimum inhibitory 
concentration of 0.63 ug/ml of tylosin tartrate is used, the required 
drug release. rate can be calculate based on tear flow rate data for 
catUe. As mentioned before, Sla·tter and Edwards (1982) have measured 
bovine tear flow rates as being 1.96 ± 1.84 ml/hr. Using these data, a 
minimum release rate of the order of 1.2 to approximately 2.4 ug/hr of 
tylosin tartrate is required. These values are useful in design 
considerations for the system to be described. 
Calculation of release ~for drug release system 
Leytem (1984) has made disk-shaped laminates of 90:10 MMA-HEMA 
copolymer ·which contained tylosin tartrate. The disks were studied for 
release characteristics in five-day in vitro experiments, He obtained 
the release results of approximately 1 - 33.3 ug/hr (for up to 84 hrs) 
from the controlled release disks containing 50 mg of tylosin tartrate. 
Weiss (1985) has measured release rates from a reservoir system and a 
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monolithic system. The reservoir system did not provide consistent 
release characteristics, while ten monolithic devices provided similar 
release profiles and gave a minimum release rate of at least 5 ug/hr 
throughout nine days. He concluded that the monolithic system could be 
applied for the treatment of pinkeye in cattle, since the rate seen from 
the monolithic devices after nine days was above the calculated minimum 
release values (approximately 2.4 ug/hr) desired. In his system, the 
drug release rates were seen to be inversely proportional to time, but 
not to the one-half power. 
In general, the determination of the release pattern of the delivery 
device is essential in anticipating release rates for similar systems. 
The release rate can be a function of device geometry and coating 
copolymer composition. The geometry of the device of the current study 
is that of a cylinder, the outer portion of which contains the active 
antibacterial agent. The cylinder is joined at both ends, and a ring 
shape results •. As mentioned before, the solubility of the solute in the 
polymer matrix determines the type of system. Therefore, if the 
solubility of tylosin tartrate in the hydrogel is below or at the 
solubility limit (saturation solubility), the system will be a dissolved 
system. This system depends on the diffusivity of tylosin tartrate in a 
homogeneous matrix containing the dissolved drug. For a drug dissolved 
in a device having the cylinderical geometry, the fractional release 
(Mt/M~) and the release rate (dMt/dt) at any time can be obtained easily 
by using the equations in Table 1. However, our system is not exactly a 
cylinder model or a slab model. Therefore, when those equations are 
applied to our system, any assumptions must be considered carefully. 
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METHODS AND MATERIALS 
Production of MMA:HEMA Copolymers (90:10 and 25:75) 
The MMA:HEMA copolymers were made in a batch process. The following 
materials were added in the order listed to a one-liter Erlenmeyer flask: 
570 ml of absolu·te ethanol, 380 ml of type-one water, 6.1 ml of HEMAl, 
46.6 ml of MMA2, 0.25 gm of reagent grade sodium persulfate and 0.125 gm 
of reagent grade potassium persulfate to provide a MMA:HEMA copolymer on 
a 90:10 molar basis. For a 25:75 (MMA:HEMA) copolymer, the added amount 
of the materials was the same as the above except that 37.2 ml of HEMA 
and 10.9 ml of MMA were added to the water, ethanol and initiator 
mixture. The flask was sealed with a rubber stopper and the contents 
were bubbled vigorously with nitrogen for 30 minutes. After thirty 
minutes, the nitrogen pressure was adjusted to a slow continuous bubbling 
throughout the ten day copolymerization period. The reaction was carried 
out at room temperature. On the tenth day, the 90:10 copolymer was 
present in the form of a white sticky precipitate. The solution 
containing the copolymer was added to three liters of water. However, 
the 25:75 solution did not exhibit a change in color until the copolymer 
solution was added to three liters of type-one water even though the 
reaction was complete. The liquid was filtered through Whatman 
I-quantitative filter paper in a Buchner funnel by using a vacuum. Each 
time the funnel was full of precipitate, the precipitate was washed four 
1 
Polysciences Inc., Lot #2-2405, Ophthalmic Grade, Warrington, Pa. 
2 
Aldrich Chemical Co. Inc., Lot #041557, Milwaukee, Wis. 
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times with 25 ml of water, and was placed into a glass container for 
drying. This container was covered with filter paper which prevented 
contaminants from entering during the drying period. The copolymer was 
dried in an oven at 50°c for five days under a vacuum (25 in. Hg) • 
. Fabrication of Controlled Release System 
Preparation of copolymer/drug mixture 
Monolithic devices used in this study were made by dip-coating a 
polymer tube. The tube was dipped into a drug/copolymer mixture and 
dried; this process was repeated several times to build up a surface 
layer of the drug and copolymer. 
In order to reduce the time required for a complete dissolution of 
the copolymer in the solvent, the copolymer particles were crushed or 
ground. For the 90:10 copolymer, a ceramic crucible was used to grind 
the hard, brittle copolymer. However, the 25:75 copolymer was a 
transparent, glassy material after drying, and was not easy to grind or 
crush. Liquid nitrogen was used to break down this material into a small 
particles (by adding liquid nitrogen while crushing). One gram of the 
copolymer powder was added to 20 ml of dimethyl formamide, mixed, and the 
mixture was heated at 5o 0 c for six hours to dissolve the polymer. Then, 
the copolymer/drug mixture was made by first cooling the solution at room 
temperature and then adding 500 mg (or 1000 mg) of tylosin tartrate to 
the solution and mixing. One half gram of tylosin tartrate was easily 
dissolved in the copolymer/solvent mixture. The 25:75 copolymer required 
more time for dissolution in the solvent than for the 90:10 copolymer. 
The finished copolymer/drug mixture became a yellow, viscous solution. 
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Preparation of mandrel 
All the devices were fablicated by dip-coating ring shaped plastic 
tubes. These mandrels were made by inserting a copper wire through a 
piece of tubing such as Silas tic tubing3, Teflon4, or polyvinylchloride 
tubings and wrapping the tubing (containing the wire) around a cylinder 
form of the correct diameter (35 - 40 mm). If the mandrel material was 
Teflon, the mandrel was soaked overnight in a soap solution6 and dried in 
air without rinsing to improve subsequent adherence of the copolymer. 
Any particular mandrel was weighed before and after coating to establish 
the weight of the copolymer-drug coating, and the drug loading of a ring 
device was calculated on the basis of the original drug:copolymer ratio. 
Dip-coating process 
The mandrel was dipped into the copolymer/drug mixture and was hung 
in a drying chamber containing nitrogen and Drierite (Caso4) to eliminate 
moisture. The moisture in the air can otherwise cause the copolymer 
layer to swell. In this study, two different compositions of copolymer, 
90:10 and 25:75, were prepared to evaluate the effects of the drug 
loading and the copolymer composition on drug release rates. Each coat 
3 Dow Corning, Silastic medical grade tubing, 
Size: 0.02S"(I.D.)x0.047"(0.D.), Midland, Mich. 
4 
Cole-Parmer, Cat.llP/N 6417-21. Size: 0.022"(I.D.)x0.042"(0.D.), 
Chicago, Ill. 
5 Becton, Dickinson and Co., Transparent/radiopaque type, 
Sizes: 0.034"(I.D.)x0.046"(0.D.) and 0.020"(I.D.) x 0.036"(0.D.), 
Rutherford, N. J. 
6 Proctor and Gamble, Ivory Snow Flakes, Cincinnati, o. 
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deposited 10-15 mg of copolymer/drug mixture on the mandrel, so nine to 
fifteen coats of solution were required to deposit the desired amounts of 
drug and copolymer on the devices. In the case of working with the 25:75 
copolymer, precoating with 90:10 copolymer improved the ease of applying 
(subsequent) coatings with the 25:75 copolymer. The 100 mg drug loading 
in a copolymer was more yellowish arid more bri t Ue than the that of 50 mg 
drug loading. The 50 mg loading for a 90:10 copolymer exhibited a 
smooth, transparent surface. The 25:75 copolymer ring device had a less 
smooth surface with a straw tint compared with the 90:10 ring devices. 
As the solvent (dimethyl formamide) in the copolymer/drug mixture .was 
capable of dissolving certain plastics such as PVC, the physical 
properties of the PVC tubing were changed somewhat after dip-coating; the 
inner PVC tube of a ring device became softer and more flexible, while 
the diameter of a ring device was reduced to 85-90% of the original 
diameter. However, the Silastic or the Teflon tubing did not exhibit a 
reduction in diameter, 
Production of finished ring device 
After drying dip coated ring devices in the desiccator for 3 days, 
the wire was removed, and both sides of a polymer ring device were then 
joined using a short piece of a PVC connecting tube (0.020" I.D. x 
0.036" O.D.), A small bead of an adhesive such as silicone rubber or a 
mix.ture of copolymer solution and tetrahydrofuran (THF)/PVC mixture was 
used to connect the tube sides, The tips of a PVC ring device widened 
slightly compared to the rest of the tubing, which made the smaller 
dfameter joint easy to insert into a dried ring device. Twenty-four 
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monolithic type devices were fabricated for the drug release experiments; 
the coating materials and drug loadings for producing these devices are 
shown in Table 2. 
TABLE 2. Characteristics of the fabricated ring devices 
--------------------~---------------------------------------------------
Device 
number 
Mandrel 
material 
Coating 
material 
(copolymer) 
Ring device 
diameter 
(mm) 
Drug loading 
amount 
(mg) 
Joint 
material 
------------------------------------------------------------------------
011 
021 
022 
031 
032 
033 
041 
042 
043 
044 
051 
052 
053 
054 
061 
062 
063 
064 
065 
071 
072 
073 
074 
075 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas tic 
Silas,tic 
Silas tic 
Silas tic 
Silas tic 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
90: 10 
90:10 
90: 10 
90:10 
90:10 
25:75 
90: 10 
90:10 
25:75 
90:10 
90: 10 
90:10 
25:75 
25:75 
90: 10 
90:10 
90: 10 
90:10 
90: 10 
25:75 
25:75 
25:75 
25:75 
25:75 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
35 
34.5 
3~.5 
37 
35 
35 
36 
36.5 
36.5 
36 
51.8 
49.9 
49. 6 
52.2 
109.7 
44.6 
48.5 
101.8 
61.5 
111.2 
116.5 
99.9 
53.8 
56.9 
50.8 
48.0 
52.8 
49.4 
55 .2 
48.7 
54.9 
57.3 
so. 5 
56.1 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
Copper wire 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
PVC 
-------------------------------------------------------------------------
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Drug Release Process 
A continuous flow apparatus was used in the tylosin tartrate release 
experiment. This apparatus was comprised of a SOOml flask, a peristaltic 
pump, a drug elution system, and a water bath as shown in Figure 10. 
DRUG ELUTION SYSTEM 
WATER BATH, 37°C PERISTALTIC PUMP RESERVOIR 
FIGURE 10. Apparatus for drug release experiment 
Mammalian Ringer's solution7 was used for the elution solution in the 
flask. The drug elution system was placed in the water bath. Each 
device was put into the inner ring-shaped hole of drug elution system to 
perm! t subsequent measurement of the amount of drug released at a 
specific time. The temperature of elution solution in the elution system 
was maintained at 37°C during the entire experiment period. In order to 
adjust the flow rate and the operating temperature of the elution 
solution during the release experiment, three methods were studied: use 
7 8.60 g NaCl, 0.30 g KCl. 0.33 g CaC1 2 in 1.0 liter type-one water. 
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of a cassette pumps, of a syringe pump9, and of a flow meter, The 
comparison of the three methods is listed in Table 3. 
TABLE 3. Comparison of three different methods for a continuous flow 
apparatus 
ment 
m 
Flow meter Syringe pump 
. ' 
Cassette pump 
-------------------------------------------------------------------------
Maximum 
operating 
capacity 
Flow rate 
adjustment 
9 days/unit 
poor 
1 day/unit 9 days/unit 
good poor 
-------------------------------------------------------------------------
Temperature 
adjustment 
good good good 
-------------------------------------------------------------------------
Sampling 
Performance 
test before 
experiment 
good 
necessary 
excellent excellent 
not necessary necessary 
-------------------------------------------------------------------------
The samples collected from the drug elution system were stored in 
small vials. The sampling time was an important factor in determining 
the release profiles seen for the continuous elution model. Since 
sequential samples obtained in the initial period (up to 2 days) 
typically contained rapidly increasing concentrations of drug (Weiss, 
1985), a short sampling time period was necessary within the initial two 
day period, In addition, other sampling frequencies were used in this 
experiment, 
8 
Cassette pump, Monostat, New York, N.Y. 
9 
Dual infusion/wi·thdrawal pump, Model/I 945 and 946, Harvard 
Apparatus Co·. , Millis, Mass. 
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Table 4 lists the conditions of the release process for each device, 
TABLE 4, Conditions of drug release experiment for each device 
-~-----------------------------------------------------------------------
Device 
number 
011 
021-022 
031-033 
041-043 
044 
051-075 
Elution fluid 
name flow rate 
(ml/hr) 
Ringer's 2 
Ringer's 2 
Ringer's 2 
Ringer's 2 
Ringer's 2 
Ringer's 2 
Equipment 
(pump) 
syringe 
syringe 
syringe 
syringe 
cassette 
cassette 
Sample collection 
frequency 
1 hour and random 8 
1 hour and 7 hours 
8 hours 
8 hours 
8 hours 
8 hours 
-------------------------------------------------------------------------8 Every hour as well as additional random sample, 
Each device was examined using a stereomicroscope before and after the 
relea.se experiment to check for poor seals around the connected parts or 
for surface cracks. Also, several were examined by scanning electron 
microscopy to check for surface structural defects. 
Quantitative Analysis of Tylosin Tartrate 
After the release experiment, the samples were dried in an oven at 
50°c. Then, a volume of water was added to the dried samples in 
particular quantities related to the anticipated concentration of drug 
and associated thin layer chromatography (TLC) requirements. For 
example, if one sample was expected to release 160 ug/hr of drug, 100 ul 
- 800 ul of water was added to the dried sample to make a concentration 
in the range of 0.5 ug/2.5 ul - 4.0 ug/2.5 ul. TLC was used to determine 
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the amount of tylosin tartrate released from the ring device for in vitro 
tests. Whatman LKC18F 20x20 cm TLC plateslO were fully developed in.a 
standard developing chamberll containing reagent grade methanol. The 
developed plates were air-dried at room temperature for three days. The 
solvent wet no more than the bot tom 3 mm of a plate once the plate was 
placed in the chamber. A volume of 2.5 ul of each redissolved sample was 
applied onto the 2 cm region below the reverse phase/preadsorbent 
interface of a TLC plate by using a Drummond 0-10 ul micropipette12. By 
touching the edge of the drop to the preadsorbent layer of the TLC plate, 
the drop was transferred to the plate. The standard samples were four 
known concentrations of tylosin tartrate (0.5, 1.0, 2.0, and 4.0 ug/2.5 
ul) which were applied to the same plate. Since the salts in the sample 
solution have an effect on the spot size and Rf value, the standard 
solutions are made with a concentration of salts to match the ressolved 
samples closely (Leytem, 1984). For this reason, the standards were made 
with a salt concentration equal to ten times that in the original release 
medium. Four standards and six samples were applied onto a plate. The 
spots on the TLC plate were dried thoroughly before development. A 
developing solution of 85 v/o methanol and 15 v/o type-one water was used 
(prior to development, the developing chamber was equilibrated by lining 
it with Whatman 3 mm filter paper13 on the side facing the plate 
10 
Whatman Chemical Separation Inc., Clifton, N.J. 
11 
Whatman Chemical Separation Inc., Type CDC-12, Clifton, N.J. 
12 
Drummond Scientific Co., Broomall, Pa. 
13 
Whatman Limited, 18.5 cm type !-qualitative, London, England. 
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surface). Each plate was developed a distance of 8 cm above the spotting 
point. A developed plate was removed and dried at room temperature. 
Spots were visualized with an ultraviolet light source14 to give 
preliminary relative intensity information. If any samples spots were 
darker than all of the standard spots, additional subsamples were 
diluted, spotted.onto another plate, and visualized in ultraviolet light. 
Direct visualization of the spots on the developed plates was 
accomplished by spraying 10 v/o of reagent grade sulfuric acid in 
methanol onto the developed area of the plate using a sprayer15. The 
spray flow rate was 15 ml/min for approximately 15 seconds. The sprayed 
plate was placed in an oven at 100°c to 105°c for 5 minutes, and was then 
allowed to cool to the room temperature. Some fading of the dry spots 
occurred. After the initial fading, the spot in tens! ty stayed constant 
for several hours (Leytem, 1984). A quantitative analysis on the plate 
was carried out within two hours. fylosin tartrate on a plate was 
evaluated by using a Kontes fiber optic scanner16. This densitometer was 
used to measure the intensity of spots by a method of cross-scanning the 
TLC plate (perpendicular to the direction of development). The 
densitometer scan rate was 2 cm/in. The output was recorded on a chart 
recorder17 to provide peak tracings to be used for subsequent calculation 
14 
UVP, Inc., Model UVGL-25 Minerallight, San Gabriel, Cal. 
15 
Kontes, Model K-422550, Vineland, N.J. 
16 
Kontes scientific Instrument Group, Model 800, Vineland, N.J. 
17 Linear I t G C d 1 I ns rumen ts roup orp .• , Mo e 255 MM, Irvine, Cal. 
18 
Mettler Instrument Corp., Model H31AR, Princeton, N.J. 
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of peak weights. The peaks were cutout and weighedl8. The amount of 
tylosin tartrate for a sample was calculated by comparing the weight of a 
sample peak to that of a series of standards. Linear interpolation was 
used. The amount of tylosin tartrate released from the ring device was 
then calculated on the base of the amount of drug found in the TLC spot 
for the 2.5 ul volume of sample. The initial dilution of samples prior 
to spotting was taken into account. The dilution limitation of our 
sample was 50 ul of water diluting for a 1 hour sample of 2 ml. 
Preliminary In Vivo Testing 
A preliminary test of retention time of a ring device, level of 
irritation and effect on tear flow rate was made. The detectability of 
drug in the collected tear sample was measured using the TLC method. 
In addition, several ring devices for in vivo test were checked for 
their flexibility and joint strength under dry and wet conditions. A 
ring device was pushed down in two directions; one direction was parallel 
to the joint part of a ring device and another was vertical. In the case 
of the wet condition,. a ring ·device was first immersed in a saline 
solution for 1-2 hours. 
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RESULTS 
Physical Characteristics of Controlled Release System 
In the copolymerization of 25:75 HEMA/MMA, it was difficult to 
confirm whether or not the reaction was completed, since there was no 
obvious physical change as seen for the 90:10 copolymer. However, after 
ten days, the addition of water to the viscous mixture resulted in 
forming a precipitate of a white-sticky copolymer. The dried 25:75 
copolymer was a transparent, glassy material. The use of fresh 
initiators produced a good yield (85-90%). In the dipcoating work, 
multiple coats were required to deposit the desired amounts of drug and 
copolymer on the devices. The number of coats for a ring device depended 
on the composition of hydrogel, the amount of drug loading and the type 
of tubing. The average number of coats was summarized in Table 5. 
TABLE 5. The average number of coats for the finished ring device 
-----------------------------------------------------------------------
Polymer 
Drug Mandrel 
loading 
90:10 
Silas tic Teflon8 PVC 
25:75 
Silastic Teflon PVC 
------------------------------------------------------------------------
50 mg 13-15 12-13 9-10 15-18 10-12 
------------------------------------------------------------------------
100 mg 13-15 12-13 
a Tubing was presoaked in soap solution. 
Small differences in the amount of drug deposited on the ring 
devices were due to the physical characteristics of the tubings and the 
solubility of drug in the copolymers; the deviation of the average drug 
amount in the 100 mg loading had a greater value than that of 50 mg drug 
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loading because the 100 mg loading of drug compared with a 50 mg amount 
was less soluble in the same amount of copolymer. 
PVC was the best tube variety of polymer of the three for 
dip-coating, and the PVC had a smooth copolymer surface after coating. 
The advantages of using PVC tubing were flexibility, ease of fabrication 
as a ring, good retention characteristics when used in vivo, and low 
cost. The coating procedure produced a 10-15% decrease in diameter for a 
PVC ring. Table 6 lists the diameter reductions seen for the various 
types of ring devices. 
TABLE 6. Shrinkage of the diameter of ring device during fabrication 
-----------------------------------------------------------------------Device 
No. 
Diameter (mm) 
original after dip-coat 
Type of 
adhesive a 
Material 
joint mandrel 
-----------------------------------------------------------------------
011-054 
061 
062 
063 
064 
065 
071 
072 
073 
074 
075 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
35 
34.5 
35.5 
35 
37 
35 
36 
36.5 
36.5 
36 
none 
THF 
90: 10 polymer .. 
.. 
.. 
.. .. 
.. 
.. 
copper 
wire 
PVC .. .. 
.. .. 
.. .. 
.. .. 
.. 
Silas tic 
or Teflon 
PVC .. .. .. .. 
.. 
.. 
.. .. 
.. 
----3------------------------------------------------------------------THF = tetrahydrofuran 
Table 7 contains descriptions of the physical appearance of the ring 
devices. The devices are divided into five groups (according to the 
characteristics of each ring device). 
so 
TABLE 7. Physical appearance of ring devices 
-------------------------------------------------------------------------
Group Characteristics 
of ring devices 
I 
II 
90:10 copolymer 
SO mg loading 
copper wire joint 
90:10 copolymer 
100 mg loading 
copper wire joint 
Device No. 
011,021 
022,031 
041 
032,042 
044,0Sl 
OS2 
Comments 
All appeared uniform and 
transparent. No defect found under 
stereomicroscopic examination. 
A' slightly rough surface and 
yellowish. Device 041 had visible 
air bubbles and a crack in side. 
-------------------------------------------------------------------------
III 
IV 
2S:7S copolymer 
SO mg loading 
copper wire joint 
90:10 copolymer 
SO mg loading 
PVC joint 
033,043 
OS3,0S4 
061-06S 
A slightly rough surface,and a gray 
color. Had a crack of the side of 
ring. 
Smooth surface and good connection. 
Transparent, no defects. 
-------------------------------------------------------------------------
v 
2S:7S copolymer 
SO mg loading 
PVC joint 
071-07S The same as for group IV above. 
-------------------------------------------------------------------------
Color differences were observed for devices prepared under 
conditions of different drug loadings and environmental conditions. The 
90:10 copolymer (SO mg loading) devices were transparent while the 90:10 
copolymer (100 mg loading) devices were straw yellow. The 2S:7S 
copolymer (SO mg loading) devices were gray. Devices prepared' in air, 
rather than under nitrogen, were white and had a more open microstruc.ture 
on the micron size level; to insure uniformity, fabrication under a 
nitr?gen environment was preferred. The 100 mg drug loading devices had 
rougher surfaces and were more brittle than the SO mg loading examples. 
The composition of a copolymer also affected the surface condition of a 
device and the ease of coating. The 2S:7S copolymer devices were more 
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difficult to dip-coat and rougher on the surface compared with the 90:10 
copolymer devices. 
The 90:10 copolymer mixture.was a better adhesive for joining 
segments of a ring than any other adhesives such as Silicone rubber or 
tetrahydrofuran. A PVC/THF solution was also satisfactory. 
Drug Release Characteristics of Ring Device 
After the release experiment, all of the samples were dried, 
redissolved with water, and spotted on the TLC plates to evaluate the 
release rate for each sampling period. The TLC analysis data for a 
release experiment performed on a monolithic device include the 
collection time, the amount of drug in the spot, the average release rate 
over the time period, and the cumulative drug release. 
Figures 11 - 34 show the drug release characteristic curves for 
devices 011-075. All of the ring devices had similar release profiles; 
the initial release is high; then the rate decreases (as an exponential 
function) until it reaches a nearly constant level throughout the rest of 
the test period. Table 8 summarizes the drug release characteristics of 
all of ring devices. 
Table 9 summarizes release characteristics by device type. The 
devices are divided into five groups (Table 9) according to the drug 
loading amount, the geometry of device, and the type of the copolymer 
used for the ring device. 
As shown in these results, all of ring devices released measurable 
amounts of drug for nine days at levels of at least 3 ug/hr of drug. The 
initial release rate (through the first 2 days) was high, and then the 
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FIGURE 22. Drug release character is tics for ring device 052. Top: 
total release vs; time; bottom: rate vs. time 
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FIGURE 28. Drug release characteristics for ring device 064. Top: 
total. release vs. time; bottom: rate vs. time 
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FIGURE 29. Drug release characteristics for ring device 065. Top: 
total release vs. time; bottom: rate vs. time 
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total release vs. time; bottom: rate vs. time 
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total release vs. time; bottom: rate vs, time 
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FIGURE 32. Drug release characteristics for ring device 073. Top: 
total release vs. time; bottom: rate vs. time 
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TABLE 8. Summary of the drug release characteristics of each ring device 
-------------------------------------------------------------------------
Device 
No. 
Initial release 
rate 
(up to 2 days) 
ug/hr 
Release rate 
level after 
6 days 
ug/hr 
Cumulative 
release 
amount 
ug 
Ratio of 
release 
allloun t 
% 
--~-----~----------------------------------------------------------------
011 
021 
022 
031 
032 
033 
041 
042 
043 
044 
051 
052 
053 
054 
061 
062 
063 
064 
065 
071 
072 
073 
074 
075 
148 - 657 
113 - 349 
156 - 445 
77 - 315 
182 - 1921 
63 - 469 
106 - 436 
220 - 2673 
162 - 657 
240 - 2685 
251 - 3631 
216 - 3015 
104 - 1275 
101 - 1366 
92 - 682 
97 - 626 
83 - 632 
101 - 925 
62 - 629 
64 - 525 
48 - 613 
62 - 644 
55. - 671 
80 - 599 
7 - 27 
11 - 34 
10 - 32 
13 - 27 
5 - 25 
4 - 16 
7 - 21 
5 - 22 
6 - 37 
6 - 29 
10 - 20 
6 - 19 
9 - 25 
5 - 20 
3 - 22 
3 - 8 
4 - 12 
3 - 7 
6 - 13 
4 - 9 
4 - 12 
6 - 11 
4 - 10 
4 - 10 
21886 
17412 
20654 
15275 
50262 
14990 
19409 
64222 
25010 
62063 
68010 
58514 
26462 
26168 
16363 
16978 
18273 
18181 
15851 
14705 
15706 
16780 
12080 
16439 
42.3 
34.9 
41. 7 
30.9 
45.9 
33.6 
40.0 
63.l 
40.7 
55.7 
58.4 
58.6 
49.2 
46.0 
32.2 
35.4 
34.6 
36.8 
28.7 
30.2 
28.6 
29.3 
23.9 
29.3 
-------------------------------------------------------------------------
release rate decreased exponentially. A large drug loading device 
affected the release pattern in the initial period, but after this period 
the release rate was similar to that seen for the small loading examples. 
The range of ratios of the release amount to total loading amount was 
28.7-36.8% for the 90:10 copolymer (50 mg loading), 45.9-63.1% for the 
90:10 copolymer (100 mg loading), and 23.9~49.2% for 25:75 copolymer (50 
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TABLE 9. Summary of the release characteristics according to device 
types 
---~-------------------------------------------------------------------
Device 
group No. 
Device type Initial 
(polymer) release rate 
(loading) (up to 2 days) 
(joint ) ug/hr 
Release 
rate level 
after 6 days 
ug/hr 
Total 
release 
amount 
ug 
Ratio of 
release 
amount 
% 
-----------------------------------------------------------------------
011, 021 
I 022,031 
041 
90:10, 
50 mg, 
wire 
77 - 657 7 - 34 15275-
21886 
30.9-
42.3 
---------------------------------------------------------------------~-
032,042 
II 044,051 
052 
033,043 
III 053,054 
90:10, 
100 mg, 182 - 3631 
wire 
25:75, 
50 mg, 63 - 1366 
wire 
5 - 25 
4 - 37 
50262-
68010 
14990-
26462 
45.9-
63.1 
33.6-
49.2 _____ _, ________________________________________________________________ _ 
IV 061-065 
90:10, 
50 mg, 62 - 925 
PVC 
3 - 22 15851-
18273 
28.7-
36.8 
-----------------------------------------------------------------------
v 071-075 
25:75, 
50 mg, 62 - 671 
PVC 
4 - 12 12080-
16780 
23.9-
30.2 
-----------------------------------------------------------------------
mg loading). Also, group IV and V examples showed a relatively low value 
compared with those of group I, II and III due to having less surface 
area. 
Post-experiment Physical Characteristics of Ring Devices 
After a release experiment, the physical characteristics of the ring 
device were checked to evaluate the effect of having a ring device in the 
solution' for a particular period. Table 10 summarizes the results of the 
post-experiment physical examinations of the ring devices. 
• 
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TABLE 10. Post-experiment physical characteristics of the ring devices 
-------------------------------------------------------------------------
Group Characteristics 
of ring devices 
Device No. Comments 
-------------------------------------------------------------------------
I 
90:10 copolymer, 
50 mg loading, 
copper wire joint 
011,021 
022,031 
041 
surface was smooth and white color; 
all had longitudinal, irregular 
cracks and enlarged defects 
----------------------------------~--------------------------------------
II 
III 
- IV 
v 
90:10 copolymer, 
100 mg loading, 
copper wire joint 
25:75 copolymer, 
50 mg loading, 
copper wire joint 
90:10 copolymer, 
50 mg loading, 
PVC tube joint 
25:75 copolymer, 
50 mg loading, 
PVC tube joint 
032,042 
044,051 
052 
033,043 
053,054 
061-065 
071-075 
A slightly yellow color; rough; 
had longitudinal, irregular defects 
as well as a badly defective 
portion 
Rough surface and gray color; same 
original defects remained and a few 
holes occurred due to air bubbles. 
Smooth surface and strong joint; 
yellowish white color· right after 
immersion; flexible and strong; 
one or two holes due to air bubble; 
minor circular, regular cracks for 
one device. 
-------------------------------------------------------------------------
All of the ring devices changed color sometime during the beginning 
of a release experiment (within 1-2 hours), When a ring device was seen 
to swell slightly, it became white and opaque (an exception was seen for 
100 mg loading device which still had a yellow tint). The swelling 
property also increased the flexibility of ring device in the solution, 
but, after drying the ring device, the surface of ring device was very 
brittle (except for group IV and V examples). The ring device with the 
copper wire joint had longitudinal cracks. This would be undesirable for 
use in an eye. However, the ring devices with PVC joints maintained 
their shape after a release experiment, and showed better flexibility and 
rigidity. Although cracks were seen on some units, these were not 
serious. On the other hand, for the 25:75 copolymer series (group III 
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and V), a rough surface was observed (related to the difficulty of 
coating tubes with this copolymer formulation), but defects did·not grow 
to larger cracks as seen in the 90:10 copolymer, Silastic series (groups 
I and II). 
Preliminary In Vivo Testing 
In the preliminary in vivo testing, five of six cattle dislodged a 
PVC ring device within minutes of insertion. Removal was due to 
concerted movements of the lower and third eyelid. These devices had 
weak joints. Only one of six ring devices remained in an eye over 1 
week. However, no overt inflammatory reaction in the eye was seen for 
this 1 week case. A few micrograms of drug were detected in tear samples 
collected at several time periods. 
As a result of the above in vivo observations of weak joint 
strength, additional tests of the flexibility and joint strength of ring 
devices were made under dry and wet conditions for PVC joints made with a 
new adhesive based on a mixture of copolymer and THF/PVC solution. The 
results for these ring devices are listed in Table 11. 
As shown in the table, the wet and dry ring devices had reasonably 
good mechanical property characteristics such as flexibility and joint 
condition. The wet devices had better flexiblility than the dry ones. 
Even if there was a small crack due to the compressive forces used for 
the test, the ring shape was kept and the ring did not separate at the 
joint. These ring devices had a stronger joint compared with those used 
in the preliminary in vivo testing. These joints were established by 
cementing a small diameter 1 cm PVC length of tubing segment within the 
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TABLE 11. Flexibility test for ring devices under dry and wet conditions 
-------------------------------------------------------------------------
Condition 
of device 
Device 
No.a 
Result of teat Remarks 
(force/adhesive) 
----------~---------------------------------------~·-------------------
Dry 
Wet 
Crack on joint part and opposite 
MOl part, but inner joint tube kept parallel/polymer 
ring shape 
M02 
M03 
M04 
MOS 
M06 
Crack near joint part and on the 
side, but inner joint tube kept vertical/polymer 
ring shape 
No crack, very strong joint both/ polymer 
Stronger than dry test, crack on 
joint part for compressive force both/polymer 
the same as above both/polymer 
Stronger than dry test, crack on 
joint and part opposite the parallel/THF and 
compressive force polymer 
-------------------------------------------------------------------------
8 All devices were made by 90:10 copolymer (50 mg loading). 
two open ends of the PVC ring. The adhesive solution was a mixture of 
copolymer solution and a THF/ Sw/o PVC solution. 
In practice, rings are preconditioned in a saline solution for about 
8 hours, so that they are soft and pliable prior to insertion, and less 
susceptible to cracking. 
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DISCUSSION 
Preparation and selection of ring device 
The 90:10 copolymer (less hydrophilic hydrogel) was a more suitable 
dipcoating material than the 25:75 copolymer (more hydrophilic hydrogel) 
for use in preparing the matrix system. PVC ring devices appeared to be 
satisfactory for use as an ocular insert. They were rigid enough to 
retain their ring shape and were flexible enough to conform to the 
conjunctival sac. In preliminary in vivo testing, a ring device was 
retained in a cow's eye for more than 1 week. Strong joints can be 
achieved through the use of a strong adhesive such as the solution 
mixture of copolymer and THF/PVC. 
No overt inflammation was observed during this in vivo experiment 
(Dr. Rosenbusch: personal communication)l9. 
TYlosin tartrate release characteristics 
The continuous release experiments provided cons is tent results in 
the determination of the release rates of the antibiotic. The cassette 
pump provided better flow control than did the syringe pump. 
All of the ring devices showed a relatively high release rate in the 
initial period (up to 2 days) compared with the 2 to 9 day period. 
Eighty to ninety percent of the total amount of drug released over a nine 
day period was released within the first two days of an in vitro 
experiment. The release profile after two days showed an exponential 
19 
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decrease. The type of profile is probably due to the result of the 
change of the flux of drug in the coating layer of a ring device. As the 
thickness of the depletion zone increases, the diffusion distance 
increases witli time (Cardinal, 1984a). Since the flux is inversely 
proportional to the zone t;hickness, the release rate will decrease with 
time whether the concentration gradient in the zone of depletion is 
linear or not. 
The release kinetics from ring devices were influenced by the 
initial drug loading and the geometry of devices. The total drug release 
amount was proportional to the surface area of ring device. For example, 
a ring device with a diameter of 40 mm (group I and III) released more 
drug than a ring device with a diameter of 35-37 mm (group IV and V). 
When the drug loading quantity was increased from 50mg to lOOmg, the 
initial release rate was increased by 2 - 6 times. After the initial 
period, the release pattern for the 100 mg loading examples was similar 
to that of the 50 mg drug loading examples. 
As mentioned before, the copolymer composition can influence the 
diffusion coefficient in the matrix system. Copolymers of HEMA and MMA 
lead to poorly swollen hydrogels. Since hydrogels consist of 
macromolecules crosslinked to form a three dimensional network, the 
permeability for a solute can change according to the composition of 
polymer. However, in this study only a slight change in release kinetics 
was seen in a comparison for the devices made from the two formulations. 
The release rate profile for a 25:75 copolymer ring device was seen to 
exhibit a similar rate profile to that of 90:10 copolymer devices. It 
had been expected that a 25:75 copolymer device would release more drug 
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than a 90:10 copolymer device due to different diffusion coefficients for 
the two materials. After 4 days, the 25:75 copolymer devices showed more 
uniform release profiles than did the 90:10 copolymer devices. The 
release rate curves based on one-hour sampling times were smoother than 
those seen for 8-hours sampling times. 
Usually the maximum release rate for a device was noted within 8 -
10 hours after starting a release experiment. After 9 days, all of the 
ring devices provided a release rates in the range of 3 - 7 ug/hr. These 
values are above that estimated drug release rate (about 1.2 ug/hr) 
needed to treat bovine ocular infections. 
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RECOMMENDATIONS FOR FUTURE RESEARCH 
Additional detailed in vivo testing will be necessary to evaluate 
retention of rings, eye irritation levels, effects on tearing rates, and 
release characteristics, The 90:10 copolymer or 25:75 copolymer (50 mg 
loading) formulations should provide useful characteristics. The 5 w/o 
PVC-tetrahydrofuran solution and copolymer solution mixture should be 
used to connect the ring segments, 
A swab can be used to collect tears from the cow's eye. To collect 
sufficient tears in in vivo experiments, it is recommended that a tear 
sample for TLC analysis be recovered from a swab by using a small syringe 
(27G needle), and that the small sample then be directly spotted on the 
TLC plate at the time of collection, The use of a pre-wetted swab is not 
satisfactory as this dilutes the drug concentration in a tear solution 
sample and adds to the uncertainty in analytical results for the drug. 
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